Granted Patent
B2
US 12,268,678 · App. 17/665,135 · Granted Apr 8, 2025
Formulations of hydroxypyridonate actinide/lanthanide decorporation agents
Inventors:
Rebecca J. Abergel (Kensington, CA); Taylor A. Choi (South San Francisco, CA); Kenneth N. Raymond (Berkeley, CA); David K. Shuh (Oakland, CA)
A61K31/444A61K9/0019A61K9/0056A61K9/0095A61K9/1611A61K9/1623A61K9/1652A61K9/2009A61K9/2018A61K9/2054A61P39/04
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are pharmaceutical formulations comprising a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent.
Claims (24)
1. A method for treating a subject for a heavy metal exposure, the method comprising:
administering to the subject having an excess amount of heavy metal a therapeutically effective amount of a pharmaceutical composition comprising:
a 1,2-HOPO chelating agent in an amount from about 100 mg to about 1500 mg; and
sodium oleate,
decorporating, clearing, and/or reducing the excess amount of heavy metal from the subject.
2. The method of claim 1 , wherein the subject has been exposed to, has been in contact with, or contaminated by one or more metals from the lanthanide series, the actinide series, or a mixture thereof.
3. The method of claim 2 , wherein the administering results in decorporating, clearing, and/or reducing the excess amount of actinide, lanthanide, or both from one or more systems and/or organs of the subject.
4. The method of claim 1 , wherein the heavy metal comprises one or more metals from the lanthanide series, the actinide series, or a mixture thereof.
5. The method of claim 1 , wherein the heavy metal comprises lead, tin, yttrium, scandium, and/or cadmium.
6. The method of claim 1 , wherein the 1,2-HOPO chelating agent is 3,4,3-LI-1,2-HOPO.
7. The method of claim 1 , wherein the sodium oleate is present at about 70 mg to about 130 mg.
8. The method of claim 1 , wherein the sodium oleate is present at 8 to 12% of a total weight of the pharmaceutical composition.
9. The method of claim 1 , wherein the sodium oleate is about 11% of a total weight of the pharmaceutical composition.
10. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount from 300 mg to 1500 mg.
11. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount from 400 mg to 1200 mg.
12. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount from 100 mg to 300 mg.
13. The method of claim 6 , wherein the 3,4,3-LI-1,2-HOPO is present in an amount of 600 mg.
14. The method of claim 1 , wherein the pharmaceutical composition is a powder.
15. The method of claim 1 , wherein the pharmaceutical composition is a chewable tablet.
16. The method of claim 1 , wherein the pharmaceutical composition is an immediate release tablet.
17. The method of claim 1 , wherein the pharmaceutical composition is within one or more orally dispersible/dissolvable granules.
18. The method of claim 2 , wherein the administering is performed 24 hours after exposure to, contact with, and/or contamination by one or more metals.
19. The method of claim 1 , wherein the pharmaceutical composition comprises one or more additional ingredients.
20. The method of claim 19 , wherein the one or more additional ingredients comprise microcrystalline cellulose, carboxymethyl cellulose, croscarmellose sodium, guar gum, lactose monohydrate, hypromellose, magnesium stearate, povidone, crospovidone, mannitol, colloidal silicon dioxide, compressible sugar, pregelatinized starch, sodium starch glycolate, hydrogenated vegetable oil (type I), and polysorbate 80.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 1, 2023
From: ABERGEL, REBECCA J.; CHOI, TAYLOR A.; RAYMOND, KENNETH N.; SHUH, DAVID K.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 063827/0060 →
Continuity (3)
Continuation
16330601
Provisional Application
62384087
· Sep 6, 2016
References Cited (357)
US 3323857A
· Bauer
· 1967
[cited by applicant]
US 3634113A
· Fhrenbacher
· 1972
[cited by applicant]
US 4025602A
· Campbell
· 1977
[cited by applicant]
US 4278559A
· Levenson et al.
· 1981
[cited by applicant]
US 4698431A
· Raymond et al.
· 1987
[cited by applicant]
US 4891075A
· Dakubu
· 1990
[cited by applicant]
US 5442116A
· Welch et al.
· 1995
[cited by applicant]
US 5482570A
· Saurer et al.
· 1996
[cited by applicant]
US 5510091A
· Rais
· 1996
[cited by applicant]
US 5571894A
· Wels et al.
· 1996
[cited by applicant]
US 5587458A
· King et al.
· 1996
[cited by applicant]
US 5591828A
· Bosslet et al.
· 1997
[cited by applicant]
US 5624901A
· Raymond et al.
· 1997
[cited by applicant]
US 5634901A
· Alba et al.
· 1997
[cited by applicant]
US 5753204A
· Huston et al.
· 1998
[cited by applicant]
US 5826161A
· Madic et al.
· 1998
[cited by applicant]
US 5869046A
· Presta et al.
· 1999
[cited by applicant]
US 5892029A
· Raymond et al.
· 1999
[cited by applicant]
US 6221476B1
· Bruening et al.
· 2001
[cited by applicant]
US 6843917B1
· Guy et al.
· 2005
[cited by applicant]
US 6846915B2
· Raymond et al.
· 2005
[cited by applicant]
US 8361794B2
· Jakobsen et al.
· 2013
[cited by applicant]
US 8475747B1
· Johnson et al.
· 2013
[cited by applicant]
US 8557601B2
· Raymond et al.
· 2013
[cited by applicant]
US 8933526B2
· Tsakalakos et al.
· 2015
[cited by applicant]
US 9123846B2
· Le Perchec et al.
· 2015
[cited by applicant]
US 9472694B2
· Dionne et al.
· 2016
[cited by applicant]
US 9556122B2
· Raymond et al.
· 2017
[cited by applicant]
US 20020122752A1
· Fukasawa et al.
· 2002
[cited by applicant]
US 20100317117A1
· Peterson
· 2010
[cited by applicant]
US 20110250138A1
· Fan et al.
· 2011
[cited by applicant]
US 20120132277A1
· Sulima et al.
· 2012
[cited by applicant]
US 20120214843A1
· Durbin-Heavey
· 2012
[cited by examiner]
US 20160362491A1
· Mudde et al.
· 2016
[cited by applicant]
US 20190183868A1
· Abergel et al.
· 2019
[cited by applicant]
CA 3022852A1
· 2017
[cited by applicant]
CA 3035966A1
· 2018
[cited by applicant]
CA 3038670A1
· 2018
[cited by applicant]
CA 3038723A1
· 2018
[cited by applicant]
CN 104825389
· 2015
[cited by applicant]
CN 104998251
· 2015
[cited by applicant]
EP 0404097B1
· 1990
[cited by applicant]
EP 1755586A2
· 2007
[cited by applicant]
EP 3452040A1
· 2019
[cited by applicant]
EP 3509595A1
· 2019
[cited by applicant]
EP 3519034A1
· 2019
[cited by applicant]
EP 3520117A2
· 2019
[cited by applicant]
EP 3520117B1
· 2023
[cited by applicant]
JP 2008525812
· 2008
[cited by applicant]
JP 2009534639
· 2009
[cited by applicant]
JP 2019514944A
· 2019
[cited by applicant]
JP 2019532040A
· 2019
[cited by applicant]
JP 2019532182A
· 2019
[cited by applicant]
JP 7018210B2
· 2022
[cited by applicant]
WO WO199301161A1
· 1993
[cited by applicant]
WO WO199316185A2
· 1993
[cited by applicant]
WO WO2006028523
· 2006
[cited by applicant]
WO WO2006072620A1
· 2006
[cited by applicant]
WO WO2007098934A1
· 2007
[cited by applicant]
WO WO2007118904
· 2007
[cited by applicant]
WO WO2010129962
· 2010
[cited by applicant]
WO WO2015077655
· 2015
[cited by applicant]
WO WO2017105565
· 2017
[cited by applicant]
WO WO2017192581
· 2017
[cited by applicant]
WO WO2018048812A1
· 2018
[cited by applicant]
WO WO2018063638A1
· 2018
[cited by applicant]
WO WO2018097871A1
· 2018
[cited by applicant]
Decision to Grant in European Application No. 17793154.0, dated Nov. 2, 2023.
[cited by applicant]
Office Action in Canadian Application No. 3,038,670, dated Nov. 1, 2023.
[cited by applicant]
Moore et al., “Eu(III) complexes of functionalized octadentate 1-Hydroxypyridin-2-ones: Stability, bioconjugation, and luminescence rosonance energy transfer studies”, Iorg. Chem. vol. 49(21):9928-9939 (2010).
[cited by applicant]
Rees et al., “Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents”, Scientific Reports, published online Mar. 13, 2018, www.nature.com/scientificreports, in …
[cited by applicant]
Office Action Dated Jan. 19, 2022 in U.S. Appl. No. 16/097,782.
[cited by applicant]
Notice of Allowance dated Oct. 29, 2021 in U.S. Appl. No. 16/330,601.
[cited by applicant]
Supplemental Notice of Allowability dated Dec. 14, 2021 in U.S. Appl. No. 16/330,601.
[cited by applicant]
Notice of Allowance dated Mar. 16, 2022 in U.S. Appl. No. 16/330,601.
[cited by applicant]
Notice of Allowance dated Jul. 27, 2022 in U.S. Appl. No. 16/330,601.
[cited by applicant]
Final Office Action dated Jul. 15, 2022 in U.S. Appl. No. 16/336,665.
[cited by applicant]
Notice of Reason for Rejection dated Mar. 10, 2022 in Japanese Patent Application No. 2018-557384.
[cited by applicant]
Non-Final Office Action dated Feb. 25, 2022, in U.S. Appl. No. 16/365,132.
[cited by applicant]
Office Action with English translation in Japanese Application No. 2019-516989, dated Aug. 5, 2022.
[cited by applicant]
Decision to Grant in European Application No. 17849400.1, dated Oct. 7, 2022, in 2 pages.
[cited by applicant]
Decision on Petition in U.S. Appl. No. 16/330,601, dated Jun. 23, 2022.
[cited by applicant]
Office Action issued in European Application No. 17793154.0, dated Sep. 20, 2022, in 4 pages.
[cited by applicant]
Decision of Refusal in Japanese Application No. 2018-557384, dated Sep. 29, 2022, with English translation, in 5 pages.
[cited by applicant]
Notice of Allowance dated Jan. 8, 2024 in U.S. Appl. No. 16/365,132, in 12 pages.
[cited by applicant]
Corrected Notice of Allowability dated Nov. 28, 2022, in U.S. Appl. No. 16/330,601.
[cited by applicant]
Notice of Allowance dated Nov. 7, 2022, in U.S. Appl. No. 16/330,601.
[cited by applicant]
Carter et al., Developing scandium and yttrium coordination chemistry to advance theranostic radiopharmaceuticals, Communications Therapy, https://doi.org/10.1038/s42004-020-0307-0, pp. 1-7 (2020).
[cited by applicant]
Notice of Allowance dated Jun. 28, 2023, in U.S. Appl. No. 16/365,132.
[cited by applicant]
Office Action in Canadian Application No. 3,022,852, dated Jun. 22, 2023, in 6 pages.
[cited by applicant]
N,N-Dimethylacetamide, C4H9NO, CID 31374—PubChem, date unknown, in 3 pages.
[cited by applicant]
Final Office Action in U.S. Appl. No. 16/336,665, dated Aug. 31, 2023.
[cited by applicant]
Corrected Notice of Allowability dated May 19, 2023, in U.S. Appl. No. 16/330,601.
[cited by applicant]
Notice of Allowance dated May 24, 2023, in U.S. Appl. No. 16/365,132.
[cited by applicant]
Advisory Action in U.S. Appl. No. 16/097,782, dated Apr. 19, 2024, in 3 pages.
[cited by applicant]
Corrected Notice of Allowability in U.S. Appl. No. 16/365,132, dated May 2, 2024, in 4 pages.
[cited by applicant]
Interview Summary in U.S. Appl. No. 16/097,782, dated Apr. 15, 2024, in 3 pages.
[cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/097,782, dated Jan. 12, 2024, in 11 pages.
[cited by applicant]
Office Action in Canadian application No. 3,022,852, dated Jan. 16, 2024, in 6 pages.
[cited by applicant]
Chatterjee et al., Excipients and Active Pharmaceutical Ingredients, American Association of Pharmaceutical Scientists, Chapter 24, pp. 347-361 (2014).
[cited by applicant]
Corrected Notice of Allowability in U.S. Appl. No. 16/365,132, dated Mar. 21, 2023.
[cited by applicant]
Notice of Allowance in Japanese Application No. 2019-516989, dated Mar. 29, 2023.
[cited by applicant]
Non-Final Office Action dated Mar. 30, 2023, in U.S. Appl. No. 16/097,782.
[cited by applicant]
Non-Final Office Action dated Mar. 28, 2023, in U.S. Appl. No. 16/336,665.
[cited by applicant]
Corrected Notice of Allowability dated Apr. 12, 2023, in U.S. Appl. No. 16/330,601.
[cited by applicant]
Notice of Allowance dated Jan. 30, 2023, in U.S. Appl. No. 16/365,132.
[cited by applicant]
Office Action dated Jan. 31, 2023, in Japanese Application No. 2022-008581.
[cited by applicant]
Abergel, R.J., et al. Biomimetic actinide chelators: an update on the preclinical development of the orally active hydroxypyridonate decorporation agents 3,4,3-L/(1,2-HOPO) and 5-LiO(Me-3,2-HOPO). Health Phys. 99(3): p.…
[cited by applicant]
Abergel, R.J., et al. “Using the Antenna Effect as a Spectroscopic Tool; Photophysics and Solution Thermodynamics of the Model Luminescent Hydroxypyridonate Complex [EuIII(3,4,3-Li(1,2-HOPO)],” Inorg. Chem, vol. 48, No.…
[cited by applicant]
Abergel Rebecca J et al, “Multidentate Terephthalamidate and Hydroxypyridonate Ligands: Towards New Orally Active Chelators”, Hemoglobin, vol. 35, No. 3, 2011, p. 276-290.
[cited by applicant]
Agbo et al., “Enhanced ultraviolet photon capture in ligand-sensitized nanocrystals,” ACS Photonics, vol. 3, pp. 547-552, 2016.
[cited by applicant]
Agbo et al., “Ligand-Sensitized Lanthanide Nanocrystals: Merging Solid-State Photophysics and Molecular Solution Chemistry,” Inorg. Chem., vol. 55, No. 20, pp. 9973-9980, Jun. 30, 2016.
[cited by applicant]
Agency for Toxic Substances and Disease Registry (ATSDR), Toxicological profile for Plutonium. 2010, U.S. Department of Health and Human Services, Public Health Service: Atlanta, GA.
[cited by applicant]
Alderighi, et al., Hyperquad Simulation and Speciation (HySS): A Utility Program for theInvestigation of Equilibria Involving Soluble and Partially Soluble Species, Coordination Chemistry Reviews, vol. 184, pp. 311-318,…
[cited by applicant]
Allred, B. et al. Siderocalin-mediated recognition, sensitization, and cellular uptake of actinides. Proc. Nat. Acad. Sci, vol. 112, pp. 10342, (2015).
[cited by applicant]
An, D. et al., elimination profiles after delayed treatment with 3,4,3L/(1,2HOPO) in female and male Swiss-Webster mice. Int J Radiat Biol,, 90(11), pp. 1055-1061, (2014).
[cited by applicant]
An, Dahlia D et al, “From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents”, Chemico-Biological Interactions, Elsevier Science Irel…
[cited by applicant]
Ansari, S. etal. Extraction of actinides using N, N,N , N-tetraoctyl diglycolamide (TODGA): a thermodynamic study Radiochim. Acta 94, 307-312 (2006).
[cited by applicant]
Ansari, S. et al., N,N,N′, N′-Tetraoctyl Diglycolamide (TODGA): A Promising Extractant for Actinide-Partitioning from High-Level Waste (HLW), Solvent Extraction and Ion Exchange, (2006).
[cited by applicant]
Antonio, M. et al., Berkelium redox speciation, Radiochim. Acta, vol. 90, pp. 851-856, (2006).
[cited by applicant]
Argonne National Laboratory Division of Biological and Medical Research, Annual Report. 1979, Argonne National Laboratory. Division of Biological and Medical Research.: Argonne, Illinois.
[cited by applicant]
Baco, E, et al., Diphenyl-benzo[1,3]dioxole-4-carboxylic acid pentafluorophenyl ester: a convenient catechol precursor in the synthesis of siderophore vectors suitable for antibiotic Trojan horse strategies, Organic and…
[cited by applicant]
Banker, G. et al., Pharmaceutics and Pharmacy Practice, pp. 238-250, 1982.
[cited by applicant]
Banski, M. et al., “NaYF4 nanocrystals with TOPO ligands: synthesis-dependent structural and luminescent properties,” Phys. Chem. Checm. Phys., vol. 15, No. 47, pp. 19232-19241, (2013).
[cited by applicant]
Baral, T. et al., Experimental Therapy of African Trypanosomiasis With a Nanobody-Conjugated Human Trypanolytic Factor, Nature Medicine, vol. 12, pp. 580-584, 2006.
[cited by applicant]
Barthelemy, et al., Journal of Biological Chemistry, pp. 3283-3639, 2008.
[cited by applicant]
Baybarz, R. et al. Absorption spectra of Bk(III) and Bk(IV) in several media, J. Inorg. Nucl. Chem. 34, pp. 739-746, (1972).
[cited by applicant]
Bhattacharyya, M. et al., Action of DTPA on Hepatic Plutonium: III. Evidence for a Direct Chelation Mechanism for DTPA-Induced Excretion of Monomeric Plutonium into Rat Bile. Radiation Research, vol. 80, pp. 108-115, (1…
[cited by applicant]
Binz, H. et al., Engineering Novel Binding Proteins From Nonimmunoglobulin Domains, Nature Biotechnology, vol. 23, pp. 1257-1268, 2005.
[cited by applicant]
Bird, R. et al., Single-chain antigen-binding proteins, Science, vol. 242, No. 4877, pp. 423-426, 1988.
[cited by applicant]
Boersma, Y. et al., DARPins and other repeat protein scaffolds: advances in engineering and applications, Current Opinion in Biotechnology, vol. 22, No. 4, pp. 849-857, 2011.
[cited by applicant]
Bunin, D. et al., Dose-dependent efficacy and safety toxicology of hydroxypyridinonate actinide decorporation agents in rodents: towards a safe and effective human dosing regimenm Radiat Res,, vol. 179(2), pp. 171-182, …
[cited by applicant]
Bünzlil, Jean-Claude G. “Lanthanide Luminescence for Biomedical Analyses and Imaging,” Chem. Rev. vol. 110, No. 5, pp. 2729-2755, (2010).
[cited by applicant]
Bünzlil, Jean-Claude G. et al. “Taking advantage of luminescent lanthanide ions,” Chem. Soc. Rev., vol. 34, No. 12, pp. 1048-1077, (2005).
[cited by applicant]
W.T. Carnall, A systematic analysis of the spectra the trivalent actinide chlorides in D3h site symetry, Argonne National Laboratory, Argonne , Illinois, USA, 1989.
[cited by applicant]
Carott, M. et al., Distribution of plutonium, americium and interfering fission products between nitric acid and a mixed organic phase of TODGA and DMDOHEMA in kerosene, and implications for the design of the “EURO-GANE…
[cited by applicant]
Carrot, M. et al. Neptunium Extraction and Stability in the GANEX Solvent: 0.2 M TODGA/0.5 M DMDOHEMA/Kerosene, Solvent Extraction and Ion Exchange, (2012).
[cited by applicant]
Captain, et al., Engineered Recognition of Tetravalent Zirconium and Thorium by Chelator-Protein Systems: Toward Flexible Radiotherapy and Imaging Platforms, Inorganic Chemistry, vol. 55, pp. 11930-11936, 2016.
[cited by applicant]
Cassatt, D. et al., Medical countermeasures against nuclear threats: radionuclide decorporation agents., Radiat Res, vol. 170 (4), pp. 540-548, (2008).
[cited by applicant]
Chang, p. et al., Analytical Methods for the Bioavailability Evaluation of Hydroxypyridinonate Actinide Decorporation Agents in Pre-Clinical Pharmacokinetic Studies. J Chromatograph Separat Techniq, 2012.
[cited by applicant]
Chen, G. et al. “Core/Shell NaGdF4:Nd3+/NaGdF4 Nanocrystals with Efficient Near-Infrared to Near-Infrared Downconversion Photoluminescence for Bioimaging Applications,” ACS Nano, vol. 6, No. 4, pp. 2969-2977, (2012).
[cited by applicant]
Choi, T. et al., Biodistribution of the multidentate hydroxypyridinonate ligand [(14) CJ-3,4,3-L/(1,2-HOPO), a potent actinide decorporation agent. Drug Dev Res, 76(3), pp. 107-122, (2015).
[cited by applicant]
Choi, T. et al., In vitro metabolism and stability of the actinide chelating agent 3,4,3-Lf {1,2-I-/OPO). J Pharm Sci, 104(5)., pp. 1832-1838, (2015).
[cited by applicant]
Choi, T. et al., Understanding the Health Impacts and Risks of Exposure to Radiation, in Reflections on the Fukushima Daiichi Nuclear Accident, J. Ahn, et al., Editors, Springer International Publishing. p. 259-281, (20…
[cited by applicant]
Chudinov, E. et al., The separation of berkelium (III) from cerium (III), J. Radioanal. Chem. 10 41-46, (1972).
[cited by applicant]
Cortez-Retamozo, V. et al., Efficient Cancer Therapy with a Nanobody-Based Conjugate, Cancer Research, vol. 64, pp. 2853-2857, 2004.
[cited by applicant]
Cotton, S. et al. Wiley, 2006. http://www.wiley.com/WileyCDA/WileyTitle/productCd-0470010053.html.
[cited by applicant]
Daumann, L.J., et al. “New Insights into Structure and Luminescence of Eu(III) and Sm(III) Complexes of the 3,4,3-Li(1,2-HOPO) Ligand,” J. Am. Chem. Soc., vol. 137, pp. 2816-2819, (2015).
[cited by applicant]
Deblonde, et al., A New Strategy for the Purification of Heavy Actinides and Medical Radioisotopes, Advanced Techniques in Actinide Spectroscopy, 2018.
[cited by applicant]
Deblonde, et al., Chelation and stabilization of berkelium in oxidation state +IV, Nature Chemistry, vol. 9, pp. 843-849, 2017.
[cited by applicant]
Deblonde, et al., Complexation, Characterization and Separation of the Lanthanides and Actinides: Shedding Light to Subtle Differences within the f-element Series, Actinides and Rare Earths Focus Topic, 2018.
[cited by applicant]
Deblonde, et al., Solution Thermodynamic Stability of Complexes Formed with the Octadentate Hydroxypyridinonate Ligand 3,4,3-Li(1,2-HOPO): A Critical Feature for Efficient Chelation of Lanthanide(IV) and Actinide(IV) Io…
[cited by applicant]
Deblonde, G. et al. 1387—Hydropyridinonate ligands: From iron(III) to berkelium(IV) chemistry, Abstract.
[cited by applicant]
Deblonde, L. et al., Inorganic chemistry, vol. 52, No. 15, pp. 8805-8811,2013.
[cited by applicant]
Deblonde, et al., Inducing selectivity and chirality in group IV metal coordination with high-denticity hydroxypyridinones†, Dalton Transactions, No. 23, 2019.
[cited by applicant]
Deblonde, et al., Solution Thermodynamics and Kinetics of Metal Complexation with a Hydroxypyridinone Chelator Designed for Thorium-227 Targeted Alpha Therapy, Inorganic Chemistry, vol. 57, pp. 14337-14346, 2018.
[cited by applicant]
Deblonde, et al., Solution thermodynamics of hydropyridinonate 4f and 5f complexes, 28th Rare Earth Research Conference, 2017.
[cited by applicant]
Deblonde, et al., Toxic heavy metal—Pb, Cd, Sn—complexation by the octadentate hydroxypyridinonate ligand archetype 3,4,3-Li(1,2-HOPO)+, New Journal of Chemistry, vol. 42, pp. 7649-7658, 2018.
[cited by applicant]
Deblonde, et al., Ultra-selective Ligand-driven Separation of Strategic Actinides, Nature Communications, 2019.
[cited by applicant]
Delmau, L. et al., Extraction of Trivalent Actinides and Lanthanides from Californium Campaign Rework Solution Using TODGA-based Solvent Extraction System, Oak Ridge National Laboratory (2017).
[cited by applicant]
Deri, et al., Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling andEvaluation of 3,4,3-(Li-1,2-HOPO), Journal of Medicinal Chemistry, vol. 57, No. 11, pp. 4849-4860, 2014.
[cited by applicant]
Deri, et al., Bioconjugate Chemistry, vol. 26, No. 12, pp. 2579-2591, 2015.
[cited by applicant]
Deri, et al., A Superior Bifunctional Chelator for 89Zr ImmunoPET, Bioconjugate Chemistry, vol. 26, No. 12, pp. 2579-2591, 2015.
[cited by applicant]
Designing a Process for Selecting a Site for a Deep-Mined, Geologic Repository for High Level Radioactive Waste and Spent Nuclear Fuel, United States Nuclear Waste Technical Review Board, 1-228 (2015).
[cited by applicant]
Durbin, P. et al. Actinides in Animals and Man, in the Chemistry of the Actinide and Transactinide Elements, L.R. Morss, N.M. Edelstein, and J. Fuger, Editors, pp. 3339-3340, (2006).
[cited by applicant]
Durbin, P. et al., “Octadentate catecholamide ligands for Pu (IV) based on linear or preorganized molecular backbones”, Human Toxicology, Macmillan Publishers, Basingstoke GB, vol. 15, No. 4, pp. 352-360, 1996.
[cited by applicant]
Durbin, P. et al. Gross composition and plasma and extracellular water volumes of tissues ofa reference mouse. Health Phys, 63(4), pp. 427-442, (1992).
[cited by applicant]
Durbin, P. et al., Lecture: the quest for therapeutic actinide chelators. Health Phys, 95(5): p. 465-492., (2008).
[cited by applicant]
Dutta, S. et al., Studies on separation of 90Y and 90Sr separation from hydrochloric acidsolutions using TODGA as the extractant by SLM method, Procedia Chemistry, vol. 7, pp. 191-194. (2012).
[cited by applicant]
Fritsch, P. et al., Simplified structure of a new model to describe urinary excretion of plutonium after systemic, liver or pulmonary contamination of rats associated with Ca-DTPA treatments., Radiat Res, vol. 171 (6), …
[cited by applicant]
Fritsch, P. et al., Structure of a single model to describe plutonium and americium decorporation by DTPA treatments, Health Phys, 99(4)., pp. 553-559, (2010).
[cited by applicant]
Gans, et al., Investigation of Equilibria in Solution. Determination of Equilibrium Constants with the Hyperquad Suite of Programs, Talanta, vol. 43, pp. 1739-1753, 1996.
[cited by applicant]
Gans, et al., GLEE, a new computer program for glass electrode calibration, Talanta, vol. 51, No. 1, pp. 33-37, 2000.
[cited by applicant]
Gans, et al., Determination of equilibrium constants with the Hyperquad suite of programs, Talanta, vol. 51, No. 1, pp. 33-37, 2000.
[cited by applicant]
Gennaro, P. et al., Remington: The Science and Practice of Pharmacy, 20th ed, 2003.
[cited by applicant]
D.H. Goetz, M.A. Holmes, N. Borregaard, M.E. Bluhm, K.N. Raymond, R.K. Strong, The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition, Mol. Cell. 10 (2002) 103…
[cited by applicant]
Gorden et al. Rational Design of Sequestering Agents for Plutonium and Other Actinides, Chemical Reviews, vol. 103, pp. 4207-4282, (2003).
[cited by applicant]
Grappin L., et al., Treatment of actinide exposures: A review oJCa-DTPA injections inside CEA-COGEMA plants. Radiation Protection Dosimetry, 127(1-4): p. 435-439, (2007).
[cited by applicant]
Gregoric, M. et al. Characterization and Leaching of Neodymium Magnet Waste andSolvent Extraction of the Rare-Earth Elements Using TODGA, J. Sustain. Metall, (3), pp. 638-645, (2017).
[cited by applicant]
Grimes, T. et al., Trivalent Lanthanide/Actinide Separation Using Aqueous-Modified TALSPEAK Chemistry, Solvent Extr. Ion Exch. 32(4), pp. 378-390 (2014).
[cited by applicant]
Gutmacher, R. et al. The absorption spectra of Bk3+ and Bk4+ in solution, J. Inorg. Nucl. Chem. 29 2341-2345, (1967).
[cited by applicant]
Gutmacher, R. et al.stability of tetravalent berkelium in acid solution and the absorption spectra of Bk(IV) and Bk(III), J. Inorg Nucl. Chem, pp. 979-994, (1973).
[cited by applicant]
Harvey, Production of Actinium-225 via High Energy Proton Induced Spallation of Thorium-232. Final Technical Report DE-SC0003602, NorthStar Medical Radioisotopes, LLC, https://world wide web .osti.gov/scitech/servlets/p…
[cited by applicant]
Hobart, D. et al. ,Peterson, The Chemistry of the Actinide and Transactinide Elements—Chapter X—Berkelium, Springer, 2006.
[cited by applicant]
Hoet, R. et al., Generation of High-Affinity Human Antibodies by Combining Donor-Derived and Synthetic Complementarity-Determining-Region Diversity, Nature Biotechnology, vol. 23, pp. 344-348, 2005.
[cited by applicant]
Holliger, P. et al., “Diabodies”: small bivalent and bispecific antibody fragments, Proceedings of the National Academy of Sciences of the USA, vol. 90, pp. 6444-6448, 1993.
[cited by applicant]
Hudson, P. et al., Engineered antibodies, Nature Medicine, vol. 9, pp. 129-134, 2003.
[cited by applicant]
Husain, M. et al. Extraction chromatography of lanthanides using N,N,N′, N′-tetraoctyl diglycolamide (TODGA) as the stationary phase, Desalination 229, pp. 294-301, (2008).
[cited by applicant]
Huston, J. et al., Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-Chain Fv Analogue Produced in
[cited by applicant]
Iqbal, M. et al. , Synthesis and Am/Eu extraction of novel TODGA derivatives, Supramolecualr Chemistry vol. 22, pp. 827-837, (2010).
[cited by applicant]
Jang, H.S. et al. “Bright dual-mode green emission from selective set of dopant ions in β-Na(Y,Gd) F4:Yb,Er/β-NaGdF4:Ce,Tb core/shell nanocrystals,” Optics Express, vol. 20, No. 15, pp. 17107-17118, (2012).
[cited by applicant]
Jarvis, E., et al., Significance of Single Variables in Defining Adequate Animal Models to Assess the Efficacy of New Radionuclide Decorporation Agents: Using the Contamination Dose as an Example. Drug Development Resea…
[cited by applicant]
Burgaada, et al., Journal of Labelled Compounds and Radiopharmaceuticals, vol. 44, pp. 13-19, 2001.
[cited by applicant]
G.M. Jursich, J.V. Beitz, W.T. Carnall, G.L. Goodman, C.W. Williams, L.R. Morss, Laser induced fluorescence of 249 Bk 4
[cited by applicant]
Konzen, K. et al, Development of the Plutonium-DTPA Biokinetic Model. Health Physics, 108(6), pp. 565-573, (2015).
[cited by applicant]
Kurkoti, J. et al. Gadolinium and nephrogenic systemic fibrosis: Association or causation. 1-10 Nephrology, vol. 13, pp. 235-241, (2008).
[cited by applicant]
Kullgren, B. et al., Actinide chelation: biodistribution and in vivo complex stability of the targeted metal ions, Toxicol Mech Methods, 23(1), pp. 18-26, (2013).
[cited by applicant]
Lakowicz, Joseph R., “Energy Transfer,” Principles of Fluorescence Spectroscopy, pp. 367-394, (2006).
[cited by applicant]
Lake, D. et al., Construction and Binding Analysis of Recombinant Single-Chain TCR Derived From Tumor-Infiltrating Lymphocytes and a Cytotoxic T Lymphocyte Clone Directed Against MAGE-1, International Immunology, Vo. 11…
[cited by applicant]
Lakshminarayana, G. et al. “Cooperative downconversion luminescence in Pr3+/ Yb3+:SiO2-Al2O3—BaF2—GdF3 glasses,” Journal of Materials Research, vol. 23, Issue 11, pp. 3090-3095, Nov. 2008.
[cited by applicant]
Li, X. et al. “Engineering Homogeneous Doping in Single Nanoparticle to Enhance Upconversion Efficiency,” Nano Lett., vol. 14, No. 6, pp. 3634-3639, (2014).
[cited by applicant]
Li, C. et al. “Enhanced NIR downconversion luminescence by precipitating nano Ca5(PO4)3F crystals in Eu2
[cited by applicant]
Li, X. et al. “Nd3
[cited by applicant]
Liu, Y et al. A Strategy to Achieve Efficent Dual-Mode Luminscence of EU3
[cited by applicant]
Liu, C. et al. “Morphology and Phase-Controlled Synthesis of Monodisperse Lanthanide-Doped NaGdF4 Nanocrystals with Multicolor Photo Luminsence,” J. Mater. Chem., vol. 19, pp. 489-496, (2009).
[cited by applicant]
Liu et al., Procedures for a fast separation of berkelium from complex mixtures of reaction products, J. Radioanal. Nucl. Chem. 76 (1983) 119-124.
[cited by applicant]
Lohithakshan, K. et al., Solvent extraction studies of plutonium(IV) and americium(III) in room temperature ionic liquid (RTIL) by di-2-ethyl hexyl phosphoric acid (HDEHP) as extractant, J. Radioanal. Nucl. Chem. vol. 3…
[cited by applicant]
Loomis & Raymond, Inorganic Chemistry, vol. 30, No. 5, pp. 906-911, 1991.
[cited by applicant]
Lumetta, G. et al., An Advanced TALSPEAK Concept Using 2-Ethylhexylphosphonic Acid Mono-2-Ethylhexyl Ester as the Extractant, Solvent Extr. Ion Exch, 33(3)., pp. 211-223, (2015).
[cited by applicant]
Lundberg, D. et al., Structural Study of the N,N′-Dimethylpropyleneurea Solvated Lanthanoid(III) Ions in Solution and Solid State with an Analysis of the Ionic Radii of Lanthanoid(III) Ions, Inorg. Chem. vol. 49, pp. 44…
[cited by applicant]
Lundberg,I. et al., The size of actinoid(III) ions—structural analysis vs. common misinterpretations,, Coord Chem Rev., vol. 318, pp. 131-134, (2016).
[cited by applicant]
Martell, A. E.; Smith, R. M.; Motekaitis, R. J. NIST Standard Reference Database; National Institute of Standards and Technology: Gaithersburg, MD.
[cited by applicant]
Maynard, J. et al., High-Level Bacterial Secretion of Single-Chain Aβ T-Cell Receptors, Journal of Immunological Methods, vol. 306, pp. 51-67, 2005.
[cited by applicant]
Mimum, L. Christopher et al. “Bimodal imaging using neodymium doped gadolinium fluoride nanocrystals with near-infrared to near-infrared downconversion luminescence and magnetic resonance properties,” Journals of Materi…
[cited by applicant]
Milyukova, et al. Extraction of Bk(IV) with POM—Milyukova, 1986.pdf, J. Radioanal. Nucl. Chem. 104 pp. 81-90, (1986).
[cited by applicant]
Modolo, et al., Recovery of Actinides and Lanthanides From High-Level Liquid Waste by Extraction Chromatography Using TODGA
[cited by applicant]
Modolo, G. et al. Development of a TODGA based Process for Partitioning of Actinidesfrom a PUREX Raffinate Part I: Batch Extraction Optimization Studies and Stability Tests, Solvent Extractio nand Ion Exchange, (2007).
[cited by applicant]
Moore, E.G., et al. “An octadentate luminescent Eu(III) 1,2-HOPO chelate with potent aqueous stability,” Inorg. Chem., vol. 46, No. 14, pp. 5468-5470, (2007).
[cited by applicant]
Moore, P. et al., Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma, Blood, Vo. 117, pp. 4542-4551, 2011.
[cited by applicant]
Moore, P. et al. Liquid-liquid extraction method for the separation of cerium (IV) from berkelium (IV) and other elements, Anal. Chem. 41, 1658-1661.,(1969).
[cited by applicant]
Moore, P. et al., New method for rapid separation of berkelium (IV) from cerium (IV) by anion exchange, Anal. Chem. 39 1874-1876, (1967).
[cited by applicant]
Moos, W.H. and G.N. Shankar, Radiation Drugs—A Hot Topic. Drug Development Research, 2012. 73(5): p. 229-231.
[cited by applicant]
Morita, Y. et al. Development of TODGA Extraction Process for High-Level Liquid Waste—Preliminary Evaluation of Actinide Separation by Calculation, (2000).
[cited by applicant]
Morris, D. et al. Voltammetric investigation of the berkelium(IV/III) couple in concentrated aqueous carbonate solutions, Radiochim, pp. 125-134, (1990).
[cited by applicant]
Morss et al., The Chemistry of the Actinide and Transactinide Elements, 4th ed, Springer,(2010).
[cited by applicant]
Naasani, Imad et al., Improving the Oral Bioavailability of Sulpiride by Sodium Oleate in Rabbits, J. Pharm., vol. 47, pp. 469-473, 1995.
[cited by applicant]
Nash, K. et al,, The Chemistry of Talspeak: A Review of the Science,, Solvent Extr. Ion Exch. 33(1), , pp. 1-55, (2015).
[cited by applicant]
NCRP, Management of Persons Contaminated with Radionuclides: Handbook, in NCRP Publication. 2008: Bethesda.
[cited by applicant]
Nord, K. et al., A combinatorial library of an α-helical bacterial receptor domain, Protein Engineering, Design and Selection, vol. 8, No. 6, pp. 601, 1995.
[cited by applicant]
Nord, K. et al., Binding proteins selected from combinatorial libraries of an α-helical bacterial receptor domain, Nature Biotechnology, vol. 15, pp. 772-777, 1997.
[cited by applicant]
Nord, K. et al., Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A, European Journal of Biochemistry, vol. 268, pp. 4269-4277, 2001.
[cited by applicant]
Nugent, L. et al., Electron-transfer and fd absorption bands of some lanthanide and actinide complexes and the standard (II-III) oxidation potential for each member of the lanthanide and actinide series, J. Phys. Chem. …
[cited by applicant]
L.J. Nugent, J.L. Burnett, R.D. Baybarz, G.K. Werner, S.P. Tanner, J.R. Tarrant, O.L. Keller Jr, Intramolecular energy transfer and sensitized luminescence in actinide (III). beta.-diketone chelates, J. Phys. Chem. 73 (…
[cited by applicant]
Ostapenko, A. et al., Extraction chromatographic behavior of actinium and REE on DGA, Ln and TRU resins in nitric acid solutions, J. Radioanal. Nucl. Chem. 306, pp. 707-711, (2015).
[cited by applicant]
Oxford Dictionary of Biochemistry and Molecular Biology (Ed. Anthony Smith, Oxford University Press, Oxford, 2004).
[cited by applicant]
Parker, S et al., The McGraw-Hill Dictionary of chemical Terms, 1985.
[cited by applicant]
Payne, G. et al. Possible stabilization of the tetravalent oxidation state of berkelium and californium in acetonitrile with triphenylarsine oxide, Inorganica Chim. Acta. 139 , pp. 111-112 (1987).
[cited by applicant]
Peppard, D. et al. Isolation of berkelium by solvent extraction of the tetravalent species, J. Inorg. Nucl. Chem. 4 344-348, (1957).
[cited by applicant]
Pham, et al., Journal of the American Chemical Society, vol. 136, No. 25, pp. 9106-9115, 2014.
[cited by applicant]
Plueckthon the Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore, 269-315, 1994.
[cited by applicant]
Pokhrel, M. et al. “Stokes emission inGdF3:Nd3
[cited by applicant]
Pourmand, A. et al., Distribution coefficients of 60 elements on TODGA resin: Application to Ca, Lu, Hf, U and Th isotope geochemistry, Talanta 81, pp. 741-753, (2010).
[cited by applicant]
Radchenko et al., Application of ion exchange and extraction chromatography to the separation of actinium from proton-irradiated thorium metal for analytical purposesJournal of Chromatography, pp. 55-63, (2015).
[cited by applicant]
Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990.
[cited by applicant]
Ricano, A.et al. Combinatorial design of multimeric chelating peptoids for selective metal coordination, Chemical Science, (2019).
[cited by applicant]
Sam II, AD et al. Safety of gadolinium contrast angiography in patients with chronic renal Insufficiency Journal of Vascular Surgery, vol. 38, pp. 313-318, (2003).
[cited by applicant]
Shannon, R. et al., Revised Effective Ionic Radii and Systematic Studies of Interatomic Distances in Halides and Chalcogenides, Acta Cryst. A32, pp. 751-757, (1976).
[cited by applicant]
Shockley, W. et al. “Detailed Balance Limit of Efficiency of p-n Junction Solar Cells,” J Appl. Phys., vol. 32, No. 3, pp. 510-519, (1961).
[cited by applicant]
Smith, R.et al., NIST Critically selected stability constants of metal complexes database, NIST standard reference database, 2004.
[cited by applicant]
Stather, J, et al. Use of DTPAfor increasing the rate of elimination ofplutonium-238 and americium-241from rodents after their inhalation as the nitrates. Hum Toxicol, 4(6), pp. 573-582, (1985).
[cited by applicant]
Stockley, J. et al. The formal potential of the Bk(IV)-Bk(III) couple in several media, J. Inorg. Nucl. Chem. 34 pp. 392-393, (1972).
[cited by applicant]
Sturzbecher-Hoehne, M. et al. “A Step Towards New Curium Decontamination Strategies,” Chem. Eur. J. , vol. 20, pp. 9962-9968, (2014).
[cited by applicant]
Sturzbecher-Hoehne, M. et al., Highly Luminescent and Stable Hydroxypyridinonate Complexes: A Step Towards New Curium Decontamination Strategies, Chem.-Eur. J. 20 (32), pp. 9962-9968, (2014).
[cited by applicant]
Sturzbecher-Hoehne, M. et al., Hydroxypyridinonate Complex Stability of Group (IV) Metals and Tetravalent f-Block Elements: The Key to the Next Generation of Chelating Agents for Radiopharmaceuticals, Inorganic chemistr…
[cited by applicant]
Sturzbecher-Hoehne, M. et al. “3,4,3-Li(1,2-HOPO): In vitroformation of highly stable lanthanide complexes translates into efficacious in vivo europium decorporation,” Dalton Trans., vol. 40, No. 33, pp. 8340-8346, (201…
[cited by applicant]
Sturzbecher-Hoehne, M. et al.Intramolecular sensitization of americium luminescence in solution: shining light on short-lived forbidden 5f transitions, Dalton Trans. doi:10.1039/C6DT00328A, (2016).
[cited by applicant]
Sturzbecher-Hoehne, et al., Solution thermodynamic evaluation of hydroxypyridinonate chelators 3,4,3-Li(1,2-HOPO) and 5-LiO(Me-3,2-HOPO) for UO2(VI) and Th(IV) decorporation, Radiochimica Acta, vol. 101,No. 6, pp. 359-3…
[cited by applicant]
Suzuki, H. et al. Extraction and separation of Am(III) and Sr(II) by N,N,N ,N-tetraoctyl-3-oxapentanediamide (TODGA), Radiochim, Acta (92, pp. 463-466, (2004).
[cited by applicant]
Tachimori, S. et al. Modification of TODGA-n-DODECANE Solvent With a Monoamide for High Loading of Lanthanides(III) and Actinides(III), Solvent Extraction and Ion Exchange, (2007).
[cited by applicant]
Taylor, D. et al., Treatment of human contamination with plutonium and americium: would orally administered Ca- or Zn-DTPA be effective? Radiat Prot Dosimetry, vol. 127 (1-4, pp. 469-471, (2007).
[cited by applicant]
Thompson, S. et al, Element 97, Phys. Rev. 77 (1950) 838.
[cited by applicant]
Thompson, S. et al., Chemical properties of Berkelium, J. Am. Chem. Soc., vol. 72, pp. 2798-2801, (1950).
[cited by applicant]
Trissel, L. et al., ASHP Handbook on Injectable Drugs 4th ed, pp. 622-630, 1986.
[cited by applicant]
Turanov, A. et al., Synergistic Extraction of U(VI), Th(IV), and Lanthanides(III) from Nitric Acid Solutions Using Mixtures of TODGA and Dinonylnaphthalene Sulfonic Acid, Solvent Extraction and Ion Exchange, (2018).
[cited by applicant]
Uhlir, Linda et al., “Specific sequestering agents for the actinides. 21. Synthesis and initial biological testing of octadentate mixed catecholate-hydroxypyridinonate ligands”, Journal of Medicinal Chemistry, vol. 36, …
[cited by applicant]
Umeda, M. et al, Separation of Americium from Plutonium-Solvent Extraction Raffinate by Extraction Chromatography using TODGA Absorbent, Atlantate, (2004).
[cited by applicant]
U.S. Food and Drug Administration, Guidance for Industry Calcium DTPA and Zinc DTPA Drug Products—Submitting a New Drug Application. 2004.
[cited by applicant]
US. Food and Drug Administration, Guidance for Industry Internal Radioactive Contamination—Development of Decorporation Agents. 2006.
[cited by applicant]
U.S. Food and Drug Administration, Guidance for Industry Product Development Under the Animal Rule 2015.
[cited by applicant]
U.S. Food and Drug Administration, Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible. 2015, U.S. FDA: Washington, DC.
[cited by applicant]
Van Der Ende, B.M. et al., “Lanthanide ions as spectral converters for solar cells,” Phys Chem Chem Phys, vol. 11, pp. 11081-11095, (2009).
[cited by applicant]
Van Wijngaarden, J.T. et al. “Energy transfer mechanism for downconversion in the (Pr3
[cited by applicant]
Wadsworth, E. et al., Present status of Cerium (IV)-Cerium (III) potentials, Anal. Chem. 29 1824-1825, (1957).
[cited by applicant]
Wai, C. et al., Carboxylate-derived calixarenes with high selectivity for actinium-225, Chem Commun, pp. 377-378 , (1998).
[cited by applicant]
Wang, Z.L. et al. “Down- and up-conversion photoluminescence, cathodoluminescence and paramagnetic properties of NaGdF4 : Yb3
[cited by applicant]
Wang, Z. et al. Extraction of trivalent americium and europium with TODGA homologs from HNO3 solution, J Radioanal Nucl Chem, 313, pp. 309-318, (2017).
[cited by applicant]
Wang, F. et al. “Preparation of Core-Shell NaGdF4 Nanoparticles Doped with Luminescent Lanthanide Ions to be Used as Upconversion-Based Probes,” Nature Protocols, vol. 9, No. 7, pp. 1634-1644, (2014).
[cited by applicant]
Wawrzynczyk, D. et al. “Ligand-dependent luminescence of ultra-small Eu3
[cited by applicant]
Weidle et al., Cancer Gen. Proteo. vol. 10, pp. 155, 2013.
[cited by applicant]
Weitl, et al., Specific sequestering agents for the actinides. 3. Polycatecholate ligands derived from 2,3-dihydroxy-5-sulfobenzoyl conjugates of diaza- and tetraazaalkanes, Journal of the American Chemical Society, vol…
[cited by applicant]
Welcher, F. J. The analytical uses of ethylenediamine tetraacetic acid; 1958.
[cited by applicant]
Wermuth, C. et al., Designing Prodrugs and Bioprecursors, pp. 561-586, 2003.
[cited by applicant]
Whitaker, D. et al., Applications of Diglycolamide Based Solvent Extraction Processes in Spent Nuclear Fuel Reprocessing, Part 1: TODGA, Solvent Extraction and Ion Exchange, (2018).
[cited by applicant]
Whitcomb, R.C., Jr., et al., A public health perspective on the U.S. response to the Fukushima radiological emergency. Health Phys, 2015. 108(3): p. 357-63.
[cited by applicant]
White, D., et al., Specific Sequestering Agents for the Actinides. 16. Synthesis and Initial Biological Testing of Polydentate Oxohydroxypyridinecarboxylate Ligands, J. Med. Chem. , vol. 31 (1), pp. 11-18, (1988).
[cited by applicant]
Wilden, A. et al. Unprecedented Inversion of Selectivity and Extraordinary Difference in the Complexation of Trivalent f-Elements by Diastereomers of a Methylated Diglycolamide, Chemistry a European Journal, (2019).
[cited by applicant]
Xu, J. et al., Specific Sequestering Agents for the Actinides. 28. Synthesis and Initial Evaluation of Multidentate 4-Carbamoyl-3-hydroxy-1-methyl-2(1H)-pyridinone Ligands for in Vivo Plutonium (IV) Chelation, J. Med Ch…
[cited by applicant]
Yantasee, W. et al. Novel Sorbents for Removal of Gadolinium-Based Contrast Agents in Sorbent Dialysis and Hemoperfusion: Preventive Approaches to Nephrogenic Systemic Fibrosis (NSF), Nanomedicine, vol. 6, No., 1, pp. 1…
[cited by applicant]
Ye, S. et al. “Down conversion luminescence of Tb3
[cited by applicant]
Ye, S. et al. “Enhanced cooperative quantum cutting in Tm3
[cited by applicant]
Zou, W. et al. “Broadband dye-sensitized upconversion of near-infrared light,” Nature Photonics, vol. 6, pp. 560-564, Aug. 2012.
[cited by applicant]
Zhang et al, Novel enterobactin analogues as potential therapeutic chelating agents: Synthesis, thermodynamic and antioxidant studies Scientific Reports, vol. 6, pp. 1-12, (2016).
[cited by applicant]
Zhu, W et al. “An active-core/active-shell structure with enhanced quantum-cutting luminescence in Pr—Yb co-doped monodisperse nanoparticles,” Nanoscale, vol. 6, pp. 10500-10504, (2014).
[cited by applicant]
Zhu, X et al. Cumulative study on solvent extraction of elements by N,N, N ,N-tetraoctyl-3-oxapentanediamide (TODGA) from nitric acid into n-dodecane, Analytica Chimica Acta 527, pp. 163-168, (2004).
[cited by applicant]
Extended European Search Report Dated Mar. 24, 2020 in European App. No. 17849400.1.
[cited by applicant]
European Extended Search Report, re Application No. 17793154.0-1112/ 3452040, PCT/US2017030628, dated Nov. 21, 2019.
[cited by applicant]
International Preliminary Report on Patentability dated Nov. 6, 2018 in International Patent Application No. PCT/US2017/030628.
[cited by applicant]
International Preliminary Report on Patentability dated Mar. 21, 2019 in International Patent Application No. PCT/US2017/050121.
[cited by applicant]
International Preliminary Report on Patentability dated Apr. 11, 2019 in International Patent Application No. PCT/US2017/048910.
[cited by applicant]
International Preliminary Report on Patentability dated Apr. 11, 2019 in International Patent Application No. PCT/US2017/048934.
[cited by applicant]
International Search Report and Written Opinion dated Jul. 27, 2017 in International Patent Application No. PCT/US2017/030628.
[cited by applicant]
International Search Report and Written Opinion Dated Nov. 13, 2017 in International patent application PCT/US2017/050121.
[cited by applicant]
International Search Report Dated Dec. 21, 2017 in International Patent Application No. PCT/US2017/048910.
[cited by applicant]
International Search Report Dated May 11, 2018 in International Patent Application No. PCT/US2017/048934.
[cited by applicant]
Office Action Dated Jul. 13, 2021 in U.S. Appl. No. 16/330,601.
[cited by applicant]
Office Action Dated Aug. 16, 2021 in U.S. Appl. No. 16/097,782.
[cited by applicant]
Office Action Dated Nov. 21, 2018 in U.S. Appl. No. 15/442,441.
[cited by applicant]
Office Action Dated May 6, 2019 in U.S. Appl. No. 15/442,441.
[cited by applicant]
Office Action Dated Aug. 23, 2019 in U.S. Appl. No. 15/442,441.
[cited by applicant]
Office Action Dated Jan. 2, 2020 in U.S. Appl. No. 15/442,441.
[cited by applicant]
Office Action Dated Apr. 9, 2020 in U.S. Appl. No. 15/442,441.
[cited by applicant]
Office Action dated Jul. 28, 2021 in JP 2019-512761.
[cited by applicant]
Office Action dated Oct. 26, 2021 in Japanese Application No. 2019-516989.
[cited by applicant]
Office Action Dated Mar. 10, 2020 in U.S. Appl. No. 16/097,782.
[cited by applicant]
Office Action Dated Oct. 15, 2019 in U.S. Appl. No. 16/097,782.
[cited by applicant]
Office Action Dated Jun. 25, 2019 in U.S. Appl. No. 16/097,782.
[cited by applicant]
Supplementary Partial European Search Report, re Application No. 17873523.9, dated May 27, 2020.
[cited by applicant]
Office Action Dated Jul. 22, 2020 in U.S. Appl. No. 16/097,782.
[cited by applicant]
Japanese Office Action dated May 6, 2021 in JP 2018-557384.
[cited by applicant]
Japanese Office Action dated Oct. 26, 2021 in JP 2019-516989.
[cited by applicant]
European Search Report, re Application No. 17873523.9, dated Aug. 27, 2020.
[cited by applicant]
Supplementary Partial European Search Report, re Application No. 17857076.8, dated Oct. 7, 2020.
[cited by applicant]
Extended European Search Report, re Application No. 17857076.8, dated Jan. 19, 2021.
[cited by applicant]
Office Action Dated May 14, 2021 in European Patent Application No. 17793154.0.
[cited by applicant]
Office Action dated Jun. 10, 2021 in U.S. Appl. No. 16/365,132, dated Mar. 26, 2019.
[cited by applicant]
Notice of Allowance dated Nov. 26, 2021 in Japanese Patent Application No. 2019-512761.
[cited by applicant]
Corrected Notice of Allowability dated Nov. 10, 2021 in U.S. Appl. No. 16/330,601.
[cited by applicant]
Notice of Reasons for Rejection dated Apr. 26, 2021 in Japanese Patent Application No. JP 2018-557384.
[cited by applicant]
Office Action dated Dec. 14, 2021 in U.S. Appl. No. 16/336,665.
[cited by applicant]
Office Action in Japanese Application No. 2022-008581, dated Jun. 27, 2023, in 5 pages.
[cited by applicant]
Notice of Allowance in Japanese Application No. 2022-8581, dated Oct. 16, 2023.
[cited by applicant]
Office Action in Canadian Application No. 3,035,966, dated Oct. 23, 2023.
[cited by applicant]
Office Action in Canadian Application No. 3,038,723, dated Oct. 27, 2023.
[cited by applicant]
Corrected Notice of Allowability in U.S. Appl. No. 16/365,132, dated Mar. 26, 2024, in 3 pages.
[cited by applicant]
Final Office Action dated Aug. 1, 2023, in U.S. Appl. No. 16/097,782.
[cited by applicant]
Intention to Grant dated May 30, 2023, in European application No. 17873523.9.
[cited by applicant]
Pharmaceutics, 1997, vol. 57 No. Suppl, pp. 62-63.
[cited by applicant]
Intention to Grant dated May 18, 2022, in European Application No. 17849400.1.
[cited by applicant]
Notice of Allowance in U.S. Appl. No. 16/365,132, dated Mar. 1, 2024, in 3 pages.
[cited by applicant]
Office Action in Japanese application No. 2023-16016, dated Mar. 5, 2024, in 3 pages.
[cited by applicant]